Eyes on Asia: Takesa, Daiichi Sankyo, Biogen
This article summarizes significant biopharma dealmaking in Asia for the week ending April 26, 2026. Key actions include Takeda discontinuing an mRNA-focused research partnership with VIS, Daiichi Sankyo selling its consumer healthcare division for $1.55 billion to concentrate on oncology, and Biogen acquiring worldwide rights to felzartamab for $850 million. These moves highlight strategic shifts towards specialized areas like oncology and immunology within the Asian pharmaceutical market.
https://www.bioxconomy.com/partnering/eyes-on-asia-takesa-daiichi-sankyo-biogen